Banishing Blind Spots

Langreth, Robert
November 2006
Forbes Asia;11/13/2006, Vol. 2 Issue 19, p102
The article reports on the efforts by several companies to develop macular degeneration treatments. Genetic breakthroughs and an unlikely drug offer hope for a disease ravaging the eyes of an aging population. Two breakthrough drugs from Genentech offer hope for patients with the more severe wet form of age-related macular degeneration. At least 18 companies are now pursuing macular degeneration treatments, including stem-cell treatments.


Related Articles

  • Genentech Makes Lucentis More Widely Available.  // Review of Ophthalmology;Apr2008, Vol. 15 Issue 4, p7 

    The article reports that Genentech Inc. has implemented enhancements to the patient and provider support programs for Lucentis in the U.S. The enhancements aimed to improve enrollment timing and widen eligibility requirements. The company was able to discuss enhancements with the American...

  • DRUGS TO TREAT AGE-RELATED MACULAR DEGENERATION COMPARED IN TRIAL.  // Journal of Visual Impairment & Blindness;Mar2008, Vol. 102 Issue 3, p178 

    The article focuses on the trial initiated by the U.S. National Institutes of Health (NIH) in February 2008, on two Genentech drugs designed to treat the wet form of age-related macular degeneration (AMD), which occurs when abnormal blood vessel growth harms or destroys part of the eye. The...

  • Sources of retinal pigment epithelium (RPE) for replacement therapy. E Lee // British Journal of Ophthalmology;Apr2011, Vol. 95 Issue 4, p445 

    Stem cells, with their capacity to regenerate and replace diseased tissues, have recently been proposed as having great potential in the treatment of age-related macular degeneration (AMD). A stem cell therapeutic approach could operate to replace either the retinal pigment epithelium (RPE), the...

  • AMD stem cell 'first'. O'Hare, Ryan // Optometry Today;9/19/2014, Vol. 54 Issue 18, p5 

    The article describes the world's first stem cell treatment for age-related macular degeneration (AMD) performed on a 70-year-old woman at the Biomedical Research and Innovation in Kobe, Japan by researchers of the RIKEN Centre for Developmental Biology (CDB) on September 12, 2014.

  • Value of a soft cell. Brooks, Michael // New Statesman;12/6/2010, Vol. 139 Issue 5030, p11 

    The article examines the therapeutic uses of stem cells in medicine. It is noted that an experiment is underway using stem cells to restore the sight of several persons who possess degenerative retinal cells. A number of topics are addressed including the illegality of stem cell research in...

  • Many investigational therapies show promise for AMD. Guttman, Cheryl; LaVail, Matthew; Zeimer, Ran; Wheeler, Larry; Campochiaro, Peter A. // Ophthalmology Times;10/15/98, Vol. 23 Issue 20, p34 

    Reports on the development of treatment strategies for age-related macular degeneration (AMD). Development of an antiangiogenic agent that can inhibit the development of choroidal neovascularization; Refining of the safety of using photodynamic therapy through laser-targeted liposomes...

  • A CLEARER VISION.  // Good Medicine (Australian Consolidated Press);Mar2003, p44 

    Investigates into the efficacy of dialysis for the eyes, a blood-cleansing treatment being trialled in the U.S. and Europe. Information on age-related macular degeneration; Details of how the treatment works; Costs involved.

  • HARBOR 2-year results support individualized dosing. Mullin, David W.; Nale, Patricia // Primary Care Optometry News;Oct2013, Vol. 18 Issue 10, p12 

    The article evaluates the potential of individualized ranibizumab treatment in fighting wet age-related macular degeneration, as presented in the American Society of Retina Specialists meeting held in Toronto, Ontario from August 24 to 28, 2013.

  • Two-year results of verteporfin for AMD are promising. Charters, Lynda // Ophthalmology Times;8/1/2001, Vol. 26 Issue 15, p24 

    Presents information on the effectiveness of verteporfin in treating patients with classic choroidal neovascularization lesions associated with age-related macular degeneration. Primary and secondary outcome on the use of the ophthalmic drug; Improvement of visual acuity.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics